Spruce Biosciences Inc. (SPRB): Price and Financial Metrics

Spruce Biosciences Inc. (SPRB): $1.48

0.08 (+5.71%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add SPRB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#74 of 342

in industry

SPRB Price/Volume Stats

Current price $1.48 52-week high $3.57
Prev. close $1.40 52-week low $0.95
Day low $1.44 Volume 46,558
Day high $1.51 Avg. volume 503,718
50-day MA $1.49 Dividend yield N/A
200-day MA $2.06 Market Cap 60.25M

SPRB Stock Price Chart Interactive Chart >

SPRB POWR Grades

  • SPRB scores best on the Sentiment dimension, with a Sentiment rank ahead of 98.25% of US stocks.
  • SPRB's strongest trending metric is Quality; it's been moving up over the last 177 days.
  • SPRB ranks lowest in Momentum; there it ranks in the 19th percentile.

SPRB Stock Summary

  • With a price/sales ratio of 10.35, SPRUCE BIOSCIENCES INC has a higher such ratio than 91.15% of stocks in our set.
  • Revenue growth over the past 12 months for SPRUCE BIOSCIENCES INC comes in at 110.23%, a number that bests 95.65% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SPRB comes in at -123.85% -- higher than that of merely 4.93% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to SPRUCE BIOSCIENCES INC, a group of peers worth examining would be STTK, PIRS, ABUS, SYBX, and IKNA.
  • SPRB's SEC filings can be seen here. And to visit SPRUCE BIOSCIENCES INC's official web site, go to www.sprucebiosciences.com.

SPRB Valuation Summary

  • In comparison to the median Healthcare stock, SPRB's price/sales ratio is 200% higher, now standing at 10.8.
  • Over the past 37 months, SPRB's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for SPRB.

Stock Date P/S P/B P/E EV/EBIT
SPRB 2023-11-03 10.8 0.5 -0.9 1
SPRB 2023-11-02 11.0 0.5 -0.9 1
SPRB 2023-11-01 11.0 0.5 -0.9 1
SPRB 2023-10-31 11.2 0.5 -1.0 1
SPRB 2023-10-30 11.0 0.5 -0.9 1
SPRB 2023-10-27 10.2 0.4 -0.9 1

SPRB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SPRB has a Quality Grade of D, ranking ahead of 21.49% of graded US stocks.
  • SPRB's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows SPRB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -2.147
2020-12-31 0 NA -20.921

SPRB Price Target

For more insight on analysts targets of SPRB, see our SPRB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.20 Average Broker Recommendation 1.4 (Strong Buy)

Spruce Biosciences Inc. (SPRB) Company Bio


Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The company was founded in 2014 and is headquartered in Daly City, CA.


SPRB Latest News Stream


Event/Time News Detail
Loading, please wait...

SPRB Latest Social Stream


Loading social stream, please wait...

View Full SPRB Social Stream

Latest SPRB News From Around the Web

Below are the latest news stories about SPRUCE BIOSCIENCES INC that investors may wish to consider to help them evaluate SPRB as an investment opportunity.

Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif., November 13, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates.

Yahoo | November 13, 2023

Spruce Biosciences to Participate in the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., November 02, 2023--Spruce Biosciences to Participate in the Jefferies London Healthcare Conference

Yahoo | November 2, 2023

Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia

SOUTH SAN FRANCISCO, Calif., October 18, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced completion of target enrollment of 72 patients and closure of screening in the CAHmelia-203 clinical trial evaluating tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH) and provided updated anticipat

Yahoo | October 18, 2023

Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., August 28, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET.

Yahoo | August 28, 2023

Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

SOUTH SAN FRANCISCO, Calif., August 14, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates.

Yahoo | August 14, 2023

Read More 'SPRB' Stories Here

SPRB Price Returns

1-mo 32.14%
3-mo -33.63%
6-mo -36.62%
1-year 29.82%
3-year -94.99%
5-year N/A
YTD 34.86%
2022 -75.39%
2021 -81.65%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!